Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 53,600 shares, an increase of 26.7% from the February 28th total of 42,300 shares. Based on an average daily volume of 66,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 2.9% of the shares of the stock are sold short.

Institutional Trading of Lixte Biotechnology

A hedge fund recently bought a new stake in Lixte Biotechnology stock. TIAA Trust National Association acquired a new stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned about 4.53% of Lixte Biotechnology at the end of the most recent quarter. Hedge funds and other institutional investors own 5.10% of the company’s stock.

Lixte Biotechnology Stock Performance

NASDAQ:LIXT opened at $1.22 on Thursday. The firm has a market capitalization of $3.27 million, a price-to-earnings ratio of -0.71 and a beta of 0.19. The stock has a fifty day moving average of $1.62 and a 200 day moving average of $1.85. Lixte Biotechnology has a 52-week low of $1.02 and a 52-week high of $3.80.

Lixte Biotechnology (NASDAQ:LIXT) last announced its earnings results on Monday, March 24th. The company reported ($0.27) earnings per share for the quarter.

About Lixte Biotechnology

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.